Dual-Polymer Hydroxypropyl Guar-and Hyaluronic Acid Lubricants in Rheumatoid Arthritis

Inclusion Criteria:

1. Male or female patients in any race, 18 years (inclusive) or older.
2. Participants with a confirmed diagnosis of stable RA, determined by a rheumatologistaccording to the 2010 American College of Rheumatology (ACR)/European League AgainstRheumatism (EULAR) criteria. The systemic conditions of the enrolled patients werewell controlled by their rheumatologists during the study period.
3. Patients diagnosed with the dry eye disease (DED) by an ophthalmologist based on theTear Film & Ocular Surface Society Dry Eye Workshop II (TFOS DEWS II) dry eye severitygrading diagnostic scheme criteria.
4. At screening, dry eye associated-RA patients on a steroid-based therapy who are stablein dry eye severity but experience/complain of persistent dry eye symptoms. The results within the range of the following assessments will be defined as stableDED with persistent dry eye symptoms at the screening phase:
5. CFS score (NEI scale) 1-12.
6. OSDI score 13-50.
7. In addition, patients should fulfill the required range of the following assessmentsat Visit 2:
8. OSDI 13-50 scores
9. Non invasive TBUT 3-10 seconds
10. Schirmer's test (without anesthesia) 3-10 mm in 5 minutes
11. CFS (NEI scale) 1-12 scores
12. Patients instilled the same dry eye therapeutic regimen of steroid eye drops and/orartificial tears (but naïve to HA-containing eye drops) for at least 3 months beforethe screening phase.

Exclusion Criteria:

1. Any known allergy to any of the study medications, conjunctival allergy or infectiousdisease, history of ocular chemical or thermal burn, Stevens-Johnson syndrome (SJS) orocular pemphigoid, eyelid or lacrimal disease, any ocular operation within 6 months,grat versus host disease, non-dry-eye ocular inflammation, trauma, or presence ofuncontrolled systemic disease.
2. Patients who have a history of intraocular, lacrimal or ocular surface surgery otherthan cataract extraction.
3. Patients who received cataract extraction surgery within 6 months of screening orpatients who are planning to receive eye surgery during the study period.
4. Patients who wear corneal contact lens, have history of other severe systemicdiseases, or other conditions, in the Investigator's opinion, may preclude enrollment.
5. Patients who received poly-pharmacy treatment for the dry eye before enrollment: DEDrequires topical ophthalmic treatment other than artificial tears and steroids (i.e.,exclude auto-serum drops, diquafosol, and cyclosporine eye drops).
6. Patients with ocular conditions other than DED requiring topical ophthalmic treatment.
7. Patients who had experienced anti-rheumatic medication change within 3 months beforethe screening.